Şunu aradınız:: trombocytaggregationen (Danca - İngilizce)

plavix hæmmer trombocytaggregationen.
plavix is an inhibitor of platelet aggregation.

selexipag hæmmer trombocytaggregationen in vitro.
selexipag is an inhibitor of platelet aggregation in vitro.

biotransformation af clopidogrel er nødvendig for at hæmme trombocytaggregationen.
biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation.

clopidogrel er et prodrug, hvor en af metabolitterne hæmmer trombocytaggregationen.
clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.

biotransformation af clopidogrel er nødvendig for at frembringe hæmning af trombocytaggregationen.
biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation.

integrilin hæmmer trombocytaggregationen, men synes ikke at påvirke trombocytternes levedygtighed.
integrilin inhibits platelet aggregation, but does not appear to affect the viability of platelets.

trombocytopeni integrilin hæmmer trombocytaggregationen, men synes ikke at påvirke trombocytternes levedygtighed.
thrombocytopaenia integrilin inhibits platelet aggregation, but does not appear to affect the viability of platelets.

18 trombocytaggregationen in vitro og forlængede overhudsblødning in vivo, men forårsagede ikke spontan blødning.
in rats, dasatinib inhibited platelet aggregation in vitro and prolonged cuticle bleeding time in vivo, but did not invoke spontaneous haemorrhage.

samtidig indgift af heparin havde ingen virkning på hæmningen af trombocytaggregationen induceret af clopidogrel.
co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.

apixaban har ingen direkte effekt på trombocytaggregationen, men hæmmer indirekte trombocytaggregationen induceret af trombin.
apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.

hos rotter hæmmede dasatinib trombocytaggregationen in vitro og forlængede overhudsblødning in vivo, men forårsagede ikke spontan blødning.
in rats, dasatinib inhibited platelet aggregation in vitro and prolonged cuticle bleeding time in vivo, but did not invoke spontaneous haemorrhage.

clopidogrel skal metaboliseres af cyp450-enzymer for at danne den aktive metabolit, der hæmmer trombocytaggregationen.
clopidogrel must be metabolised by cyp450 enzymes to produce the active metabolite that inhibits platelet aggregation.

den aktive tiolmetabolit, som er blevet isoleret in vitro, binder hurtigt og irreversibelt til trombocytreceptorerne, hvorved trombocytaggregationen hæmmes.
the active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.

trombocytaggregation og kapillærblødningstid vendte gradvist tilbage til baselineværdierne, almindeligvis inden for 5 dage efter behandlingens ophør.
platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued.